TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04313530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS treatment fatigue is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks connectivity changes involved in the processing of fatigue signals.
Study: NCT00415493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold-dry air provocation
Description: 15 minute exposure to cold-dry air by nasal mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold-dry air provocation
Description: 15 minute exposure to cold-dry air by nasal mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-moist air provocation
Description: 15 minute exposure to warm-moist air by nasal mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm-moist air provocation
Description: 15 minute exposure to warm-moist air by nasal mask
Study: NCT00262743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day
Study: NCT03379233

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Concept2 inhaler
Description: Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concept2 inhaler with patient application
Description: Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
Study: NCT00965484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Genotropin Pen
Description: Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
Study: NCT00315211

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Topotecan
Description: Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Docetaxel
Description: Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
Study: NCT00848211

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection on Day 0, Day 28, and Day 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.03mg)
Description: Subcutaneous injection on Day 0, Day 28, and Day 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.1mg)
Description: Subcutaneous injection on Day 0, Day 28, and Day 84

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.6mg)
Description: Subcutaneous injection on Day 0, Day 28, and Day 84
Study: NCT00419003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: anticonvulsant medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: subanesthetic dose of NMDAR antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: subanesthetic dose of NMDAR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: glutamate release inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: glutamate release inhibitor
Study: NCT00125775

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Engerix-B at 0, 1, 6 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Engerix-B at 0, 1, 6 months
Study: NCT03837756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT00646867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: Twice daily topical application

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily topical application
Study: NCT00217100

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: 1 tablet a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet a day
Study: NCT01871285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Matching placebo buccal film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Matching placebo buccal film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
Study: NCT03837756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefitolimod
Description: A TLR9 agonist administered s.c. once weekly for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefitolimod
Description: A TLR9 agonist administered s.c. once weekly for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117 and 10-1074
Description: Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117 and 10-1074
Description: Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Study: NCT03746574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Curriculum
Description: 12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
Study: NCT04476537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoTreat
Description: OncoTreat is a computational pipeline that begins with a tumor expression profile and ends with a list of several candidate regimens.
Study: NCT01871285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
Study: NCT01454089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427 600 mg
Description: Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427 1000 mg
Description: Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study: NCT01871285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
Study: NCT02276547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Description: Transcatheter mitral valve replacement
Study: NCT01454089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study: NCT02093975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad air with 4G/3G SIM card
Description: iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad air with 4G/3G SIM card
Description: iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation
Study: NCT01095952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVNS ON
Description: Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
Study: NCT00745264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 100 mg Ketoprofen to 2 joints

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 400 mg ketoprofen to 4 joints

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 100 and 400 mg Ketoprofen used concomittant with heat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 100 and 400 mg Ketoprofen concomittant with moderate exercise
Study: NCT01765764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution
Description: Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution
Description: Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle to bimatoprost solution
Description: Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle to bimatoprost solution
Description: Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
Study: NCT00233220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent, multi-level intervention targeted at physicians and patients
Description: The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive usual care.
Study: NCT03786705

Intervention type: OTHER
Intervention: Massive transfusion
Description: Trauma patients who had received blood transfusion≥10 U

Intervention type: OTHER
Intervention: Non-Massive Transfusion
Description: Trauma patients who had received blood transfusion\<10 U
Study: NCT02560051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
Study: NCT00169741

Intervention type: OTHER
Group type: OTHER
Intervention: Renogram
Description: Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
Study: NCT02560051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estramustine
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estramustine
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estramustine
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
Study: NCT02041013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking Card
Description: Recordable greeting card-style discharge instruction card
Study: NCT02538549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACE4
Description: Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
Study: NCT04135261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003
Description: Intravenous (IV) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003
Description: Intravenous (IV) administration
Study: NCT04657315

Intervention type: DRUG
Group type: OTHER
Intervention: MSC11FCD
Description: Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration
Study: NCT00400634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Description: CERE-120 5.4 x 10\^11 vg

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Bilateral partial thickness burr holes placed, no intraparenchymal injections
Study: NCT01598896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol titrated to 5 mg three times daily
Study: NCT04349761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyMD1
Description: Isomyosamine 5mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyMD1
Description: Isomyosamine 5mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyMD1
Description: Isomyosamine 5mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyMD1
Description: Isomyosamine 5mg capsules
Study: NCT01598896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 0.1 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule by mouth twice daily
Study: NCT02517424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/Low CBD Cannabis
Description: Dried cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/High CBD Cannabis
Description: Dried cannabis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low THC/Low CBD Cannabis
Description: Dried cannabis
Study: NCT01401296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: Behavioral: the wait-list group receives Deprexis after 8 weeks